1. Impact of common risk factors of fibrosis progression in chronic hepatitis C. Issue 10 (11th September 2014) Authors: Rüeger, S; Bochud, P-Y; Dufour, J-F; Müllhaupt, B; Semela, D; Heim, M H; Moradpour, D; Cerny, A; Malinverni, R; Booth, D R; Suppiah, V; George, J; Argiro, L; Halfon, P; Bourlière, M; Talal, A H; Jacobson, I M; Patin, E; Nalpas, B; Poynard, T Journal: Gut Issue: Volume 64:Issue 10(2015) Page Start: 1605 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P48 Telaprevir substantially improved SVR rates across all IL28B genotypes in the advance trial. (6th September 2011) Authors: Dusheiko, G M; Jacobson, I M; Catlett, I; George, S; Seepersaud, S; Ramachandran, R; Sussky, K; Kauffman, R S; Botfield, M Journal: Gut Issue: Volume 60:(2011)Supplement 2 Page Start: A23 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P70 Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV Treatment-Naïve patients: final results of phase 3 ADVANCE Study. (6th September 2011) Authors: Dusheiko, G M; Bengtsson, L; Adda, N; Kauffman, R; Jacobson, I M Journal: Gut Issue: Volume 60:(2011)Supplement 2 Page Start: A32 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗